Crescita Therpeutc J (TSE:CTX)
TSX:CTX
Want to see TSE:CTX full AI Analyst Report?
CTX Stock Chart & Stats
C$0.47
-C$0.02(-3.39%)
At close: 4:00 PM EST
C$0.47
-C$0.02(-3.39%)
Day’s Range― - ―
52-Week RangeC$0.40 - C$0.76
Previous CloseN/A
Volume9.50K
Average Volume (3M)12.63K
Market Cap
C$13.96M
Enterprise ValueC$5.72M
Total Cash (Recent Filing)C$8.58M
Total Debt (Recent Filing)C$334.00K
Price to Earnings (P/E)―
Beta-0.79
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding18,613,937
10 Day Avg. Volume2,470
30 Day Avg. Volume12,630
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)0.58
Price to Sales (P/S)0.43
P/FCF Ratio12.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage (debt-to-equity ~0.03) provides durable financial flexibility to fund R&D, clinical programs and commercialization without heavy reliance on external debt. This reduces solvency risk, preserves optionality for opportunistic investment or M&A, and supports multi-quarter planning.
Improving Free Cash FlowPositive and growing free cash flow after prior negative years signals improving cash discipline and internal funding capacity. Sustained FCF helps finance working capital, R&D, and commercialization without frequent equity raises, lowering dilution risk and improving longer-term self-funding prospects.
Profitability ReboundReturn to positive EBITDA and healthy low-50% gross margins indicate solid underlying product economics and operational leverage. This foundation improves the likelihood that operating profits can be sustained and reinvested into growth, aiding durable earnings recovery over coming quarters.
Bears Say
Top-line InconsistencyTTM revenue contraction after prior growth undermines predictability of revenue expansion. Unstable top-line trends complicate capacity planning, delay margin normalization, and make it harder to model sustainable cash generation, increasing execution risk across future reporting periods.
Margin CompressionEroding margins and only modest net profitability reduce the cushion for R&D and commercialization spending. Persistent compression limits internal reinvestment, raises the probability of external financing if costs remain elevated, and slows durable improvement in returns on capital.
Volatile Cash & EarningsHistoric volatility between cash flow and reported earnings and a recent decline in operating cash flow increase funding and execution uncertainty. Timing swings in working capital or one-off items can force reactive financing or cutbacks, raising medium-term operational risk.
Crescita Therpeutc News
CTX FAQ
What was Crescita Therpeutc J’s price range in the past 12 months?
Crescita Therpeutc J lowest stock price was C$0.40 and its highest was C$0.76 in the past 12 months.
What is Crescita Therpeutc J’s market cap?
Crescita Therpeutc J’s market cap is C$13.96M.
When is Crescita Therpeutc J’s upcoming earnings report date?
Crescita Therpeutc J’s upcoming earnings report date is May 13, 2026 which is in 12 days.
How were Crescita Therpeutc J’s earnings last quarter?
Crescita Therpeutc J released its earnings results on Mar 31, 2026. The company reported -C$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.038.
Is Crescita Therpeutc J overvalued?
According to Wall Street analysts Crescita Therpeutc J’s price is currently Overvalued.
Does Crescita Therpeutc J pay dividends?
Crescita Therpeutc J does not currently pay dividends.
What is Crescita Therpeutc J’s EPS estimate?
Crescita Therpeutc J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescita Therpeutc J have?
Crescita Therpeutc J has 18,613,937 shares outstanding.
What happened to Crescita Therpeutc J’s price movement after its last earnings report?
Crescita Therpeutc J reported an EPS of -C$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Crescita Therpeutc J?
Currently, no hedge funds are holding shares in TSE:CTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Crescita Therpeutc J
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Technical Analysis
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―